Pramod Thomas is a senior correspondent with Asian Media Group since 2020, bringing 19 years of journalism experience across business, politics, sports, communities, and international relations. His career spans both traditional and digital media platforms, with eight years specifically focused on digital journalism. This blend of experience positions him well to navigate the evolving media landscape and deliver content across various formats. He has worked with national and international media organisations, giving him a broad perspective on global news trends and reporting standards.
ONLINE fashion retailer Boohoo’s decision to exclude Frasers Group from key investor meetings has stirred tensions with its largest shareholder, Mike Ashley.
New CEO Dan Finley, appointed last month, plans to meet with major shareholders, including Schroders, but no session is scheduled with Frasers, which now owns a 27 per cent stake in Boohoo, reported the Times.
Frasers alleged that Boohoo ignored multiple requests for meetings, despite claims of openness by Boohoo, labelling the company’s communication as insincere.
“Claims that they have tried to engage is a complete fabrication. Frasers has asked several times to meet with their new CEO and all requests have been met with silence," a source close to Frasers told the newspaper.
The dispute between the two retailers has been building, with Ashley previously pressing for the CEO role himself after what he calls Boohoo’s “dismal performance” and falling share value.
Instead, Boohoo promoted Finley, formerly head of Debenhams, a decision Frasers criticises as hasty and ill-advised. Frasers also raised concerns over Boohoo’s recent refinancing, calling it poorly executed.
Boohoo and Frasers remain sceptical of each other’s motives. Frasers claims it seeks to support Boohoo’s recovery, as the fashion retailer has lost around 90% of its market value due to increasing competition.
However, Boohoo said Frasers may be acting in self-interest, urging Ashley to clarify whether he intends to purchase any of Boohoo’s brands, such as Debenhams or Karen Millen, if Boohoo’s struggles continue.
Also, the firm has shown willingness to appoint a Frasers-nominated non-executive director under specific conditions. Meanwhile, Frasers has requested a shareholder meeting to propose Ashley as CEO, although no date has been set for this vote.
Both Frasers and Boohoo spokespeople declined to comment
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.